Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia

被引:37
|
作者
Haese, A
Graefen, M
Noldus, J
Hammerer, P
Huland, E
Huland, H
机构
[1] Department of Urology, University Clinic Eppendorf, Hamburg
来源
JOURNAL OF UROLOGY | 1997年 / 158卷 / 06期
关键词
prostate-specific antigen; prostatic neoplasms; prostatic hypertrophy;
D O I
10.1016/S0022-5347(01)68192-8
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We correlated prostatic volume with the ratio of free-to-total prostate specific antigen (PSA) in serum from patients with prostatic cancer or benign prostatic hyperplasia (BPH) to evaluate how prostatic volume influences the ratio. Materials and Methods: We evaluated sera from 395 patients (mean age 65 years, range 45 to 88) with prostate cancer (239) or BPH (156) for total PSA, free PSA and ratio of free-to-total PSA. For detection of total and free PSA we used an Immulite* free and total PSA assay. Prostatic volume was determined With transrectal ultrasonography. Prostatic volume in BPH and prostate cancer patients was divided into 10 ml. groups, and mean ratio of free-to-total PSA was calculated for each volume group and both diseases. For statistical analysis Mann-Whitney U and Kruskal-Wallis tests were performed in addition to calculation of sensitivity and specificity, and receiver operator curves for prostates 60 ml. or less and greater than 60 ml. Results: For BPH patients the mean ratio of free-to-total PSA was 14.64 to 25.14% without a close relation to prostatic volume. In prostate cancer patients a proportional increase from 8.45 to 19.37% in the ratio of free-to-total PSA with volume was found. Mann-Whitney U analysis revealed significant differences in prostate cancer versus BPH only in patients with prostates of 60 ml. or smaller (p = 0.0008 to 0.029). No significant differences were seen when prostate cancer and BPH patients with prostates larger than 60 ml. were compared (p = 0.082 to 0.868). Kruskal-Wallis test confirmed independence of the ratio of free-to-total PSA from prostatic volume in BPH patients (p = 0.285) but dependence in prostate cancer patients (p < 0.0001). Sensitivity was higher in patients with prostates 60 ml. or smaller (86.72%) than in patients with prostates larger than 60 ml. (66%), and specificity was lower at 45.78 and 56.16%, respectively. Conclusions: We have shown that the ratio of free-to-total PSA is influenced by prostatic volume in patients with prostate cancer. The ratio of free-to-total PSA provides useful information for differentiate BPH from prostate cancer in patients with small prostates but it is less useful in patients with larger prostates, probably because of the larger proportion of benign hypertrophic tissue.
引用
收藏
页码:2188 / 2192
页数:5
相关论文
共 50 条
  • [31] Relationship of prostate-specific antigen and prostate volume in patients with biopsy proven benign prostatic hyperplasia
    Hochberg, DA
    Armenakas, NA
    Fracchia, JA
    PROSTATE, 2000, 45 (04): : 315 - 319
  • [32] Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia
    Mochtar, CA
    Kiemeney, LALM
    van Riemsdijk, MM
    Barnett, GS
    Laguna, MP
    Debruyne, FMJ
    de la Rosette, JJMCH
    EUROPEAN UROLOGY, 2003, 44 (06) : 695 - 700
  • [33] PROSTATE-SPECIFIC ANTIGEN IN THE EXPRESSED PROSTATIC FLUID OF MEN WITH BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CARCINOMA
    KIM, ED
    SMITH, ND
    GRAYHACK, JT
    JOURNAL OF UROLOGY, 1995, 154 (05): : 1802 - 1805
  • [34] TISSUE CONCENTRATIONS OF PROSTATE-SPECIFIC ANTIGEN IN PROSTATIC-CARCINOMA AND BENIGN PROSTATIC HYPERPLASIA
    PRETLOW, TG
    PRETLOW, TP
    YANG, B
    KAETZEL, CS
    DELMORO, CM
    KAMIS, SM
    BODNER, DR
    KURSH, E
    RESNICK, MI
    BRADLEY, EL
    INTERNATIONAL JOURNAL OF CANCER, 1991, 49 (05) : 645 - 649
  • [35] Complexed and total PSA in patients with benign prostatic hyperplasia and prostate cancer
    Tamimi, W.
    Dafterdar, R.
    Mansi, M.
    Alsaad, K.
    Alarifi, S. A.
    BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 2010, 67 (04) : 184 - 188
  • [36] Benign prostatic hyperplasia, prostate cancer
    Lebdai, S.
    PROGRES EN UROLOGIE, 2017, 27 (03): : F60 - F62
  • [37] Benign prostatic hyperplasia, prostate cancer
    Mathieu, R.
    PROGRES EN UROLOGIE, 2015, 25 : F82 - F84
  • [38] Benign prostatic hyperplasia, prostate cancer
    Mathieu, R.
    PROGRES EN UROLOGIE, 2016, 26 (01): : F20 - F22
  • [39] BENIGN PROSTATIC HYPERPLASIA AND CANCER OF PROSTATE
    BYAR, DP
    LANCET, 1975, 1 (7911): : 866 - 866
  • [40] Benign prostatic hyperplasia, cancer of the prostate
    Lebdai, S.
    PROGRES EN UROLOGIE, 2017, 27 (02): : F40 - F42